Drug Profile
GED 0507-34-Levo
Alternative Names: GED-0507; GED-0507-34; N-acetyl-GED-0507-34; NAC-GED-0507Latest Information Update: 30 Jan 2023
Price :
$50
*
At a glance
- Originator Giuliani
- Developer Nogra Pharma; PPM services
- Class Anti-inflammatories; Antiulcers
- Mechanism of Action Peroxisome proliferator-activated receptor gamma modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Acne vulgaris
- No development reported Idiopathic pulmonary fibrosis; Ulcerative colitis
Most Recent Events
- 26 Jan 2023 GED 0507-34-Levo licensed to Torii Pharmaceutical for the treatment of Acne vulgaris in Japan
- 26 Jan 2023 Efficacy and adverse events data from a phase IIb trial in Acne vulgaris released by Nogra Pharma
- 28 Oct 2022 No recent reports of development identified for preclinical development in Idiopathic-pulmonary-fibrosis in Ireland (PO)